| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥0.1B | ¥0.1B | -34.1% |
| Operating Income | ¥-8.0B | ¥-10.7B | +25.4% |
| Ordinary Income | ¥-7.9B | ¥-9.6B | +17.8% |
| Net Income | ¥-7.9B | ¥-9.6B | +17.7% |
| ROE | -20.2% | -20.4% | - |
FY2025 results show Noile-Immune Biotech with revenue of 0.1B yen (YoY -34.1%), operating loss of -8.0B yen (YoY improvement +25.4%), ordinary loss of -7.9B yen (YoY improvement +17.8%), and net loss of -7.9B yen (YoY improvement +17.7%). While loss margins compressed meaningfully year-over-year, the company remains in deep pre-revenue development phase with minimal commercial sales. Cash position stands at 39.2B yen, representing 97.7% of total assets, providing substantial runway despite ongoing cash consumption of -7.5B yen in operating cash flow. The equity ratio of 98.0% reflects an exceptionally conservative capital structure, though accumulated deficit of -41.5B yen has grown 23.7% from prior year, indicating sustained shareholder value erosion. Basic EPS deteriorated to -18.33 yen from -22.28 yen, showing continued lack of profitability.
Revenue declined 34.1% YoY to 0.05B yen, indicating the company operates primarily as a research-stage biotechnology enterprise with minimal commercial activity. The geographic revenue disclosure shows all 7.6M yen originated domestically in Japan. The revenue contraction reflects the inherent volatility of early-stage development companies dependent on sporadic licensing fees, research grants, or milestone payments rather than sustained product sales. Despite revenue weakness, operating loss improved 25.4% to -8.0B yen from -10.7B yen, driven by cost management rather than top-line expansion. The minimal gap between operating loss (-8.0B yen) and ordinary loss (-7.9B yen) indicates non-operating items contributed positively by approximately 0.1B yen, primarily from interest income of 0.1B yen earned on the substantial cash reserves. The company maintains no meaningful foreign exchange exposure or financial expenses. Net loss of -7.9B yen aligns closely with ordinary loss, with negligible income tax expense of 0.0B yen due to the loss-making position. No extraordinary items such as impairment losses, asset sales, or restructuring charges were disclosed, suggesting the reported loss stems entirely from recurring operational costs exceeding minimal revenues. This represents a revenue down/profit up pattern, where the profit improvement stems solely from expense containment rather than business expansion.
[Profitability] ROE of -20.2% reflects substantial losses against equity base, operating margin of -15,940.0% underscores the extreme mismatch between minimal revenues and fixed operating costs. The distorted margin ratios result from dividing significant operating expenses by near-zero revenue base, characteristic of pre-commercial biotech enterprises. [Cash Quality] Cash and deposits of 39.2B yen provide coverage of 53.0x against current liabilities of 0.7B yen, ensuring ample short-term liquidity. Operating cash flow to net income ratio of 0.95x indicates cash losses closely track accounting losses without material non-cash adjustments or working capital distortions. [Investment Efficiency] Asset turnover of 0.001x reflects the company's current positioning as a cash repository funding research activities rather than an asset-intensive operating business. [Financial Health] Equity ratio of 98.0% demonstrates minimal leverage, current ratio of 5,354% indicates exceptional short-term solvency, and debt-to-equity ratio of 1.02x remains conservatively low with virtually no interest-bearing debt. However, retained earnings of -41.5B yen represent accumulated losses that have eroded 51.1% of equity capital, warranting attention to cash burn sustainability.
Operating cash flow of -7.5B yen represents 0.95x of net loss, confirming that accounting losses translate directly into cash consumption with minimal non-cash adjustments. The operating cash flow subtotal before working capital changes of -7.6B yen aligns closely with final operating CF, indicating negligible working capital movements during the period. Change in inventories contributed positively by 0.1B yen, while contract liabilities decreased by 0.1B yen, suggesting fulfillment of prior period obligations. Interest and dividends received of 0.1B yen provided modest cash inflow from the substantial cash reserves. Income taxes paid of effectively zero yen reflects the loss-making position. Investing cash flow of 0.0B yen indicates no material capital expenditures or asset acquisitions, consistent with a research-focused business model requiring minimal physical infrastructure. Financing cash flow of 0.0B yen shows no debt drawdowns, equity issuances, or dividend payments during the period, with share repurchases of effectively zero yen. Free cash flow of -7.5B yen matches operating CF given zero investing outflows, representing the ongoing cash consumption rate that draws down the cash reserves at approximately 19% of beginning cash balance annually if sustained at current levels.
Ordinary loss of -7.9B yen versus operating loss of -8.0B yen shows net non-operating contribution of approximately 0.1B yen. This comprises primarily interest income of 0.1B yen earned on cash deposits, with negligible other non-operating items. Non-operating income represents 200% of minimal revenue, though this ratio reflects the distortion of near-zero sales rather than dependency on non-core activities. The interest income demonstrates prudent treasury management of the substantial 39.2B yen cash position. Operating cash flow of -7.5B yen closely tracks net loss of -7.9B yen with a ratio of 0.95x, indicating high quality of reported losses without material accrual manipulations. The absence of significant differences between cash and accrual metrics suggests transparent financial reporting, though the quality assessment centers on loss recognition rather than profit generation. No extraordinary gains or one-time benefits inflate reported results, ensuring losses represent genuine recurring operational shortfalls requiring either revenue growth or cost restructuring to achieve profitability.
Clinical development and regulatory approval risk represents the primary uncertainty, as the company's future viability depends entirely on successful advancement of pipeline candidates through clinical trials to commercialization. With current revenue of only 0.05B yen and operating losses of 8.0B yen, failure to achieve regulatory milestones would eliminate the path to profitability without material business model changes. Cash consumption sustainability poses medium-term risk, with operating cash outflow of -7.5B yen annually depleting the 39.2B yen cash reserve at approximately 19% per year. Absent revenue inflection or additional capital raising within 3-5 years, the company may face funding constraints impacting research continuity. Shareholder dilution risk emerges from likely future capital needs, as the accumulated deficit of -41.5B yen and ongoing losses suggest eventual equity financing requirements. With no debt capacity utilized and no path to positive cash flow visible in current operations, future capital raises may significantly dilute existing shareholders, particularly if executed from positions of financial pressure rather than strategic strength.
[Industry Position] (Reference - Proprietary Analysis)
Noile-Immune Biotech operates as an early-stage biotechnology development company, characterized by pre-revenue clinical research activities typical of the sector. Given the company's nascent commercial status with revenue of only 0.1B yen, traditional profitability and efficiency benchmarks provide limited comparative value. The pharmaceutical and biotechnology industry typically exhibits extended pre-commercial development phases spanning 5-15 years, during which companies maintain substantial cash reserves to fund research while accumulating significant losses. The company's operating margin of -15,940% falls well below industry medians for commercial pharmaceutical enterprises but aligns with pre-revenue development firms where operating costs vastly exceed minimal grant or licensing revenues. The equity ratio of 98.0% significantly exceeds typical industry capital structures, reflecting conservative financing with virtually no leverage compared to industry peers who often utilize 20-40% debt ratios. Cash position representing 97.7% of total assets indicates a treasury-centric balance sheet focused on research funding rather than operating asset deployment, consistent with discovery-stage biotechnology business models. The company's financial profile suggests positioning in the earliest development stages, where industry success depends on clinical advancement rather than current financial metrics.
Operating loss compression of 25.4% year-over-year to -8.0B yen despite revenue declining 34.1% demonstrates meaningful cost discipline, suggesting management focus on extending cash runway through expense management while advancing research programs. This structural operating leverage improvement represents the most significant positive trend observable in current period results. Cash reserve adequacy provides multi-year funding visibility, with 39.2B yen in liquid assets covering approximately 5 years of operations at current cash consumption rates of -7.5B yen annually, assuming no revenue growth or additional capital needs. This substantial runway enables clinical development continuity without near-term financing pressure, though the accumulated deficit expansion to -41.5B yen signals ongoing shareholder value erosion. The minimal revenue base of 0.1B yen combined with domestic-only geographic concentration indicates the company remains in research stage without commercial products, requiring successful clinical outcomes and regulatory approvals to achieve the transformational revenue inflection necessary for financial sustainability.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.